Kyowa Hakko Kirin Co., Ltd. (KY4.F)

15.40 -0.10 (-0.65%) At close: 03:29PM CEST

Kyowa Hakko Kirin Co., Ltd.

Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
https://www.kyowakirin.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 5,974

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Masashi Miyamoto Ph.D.	President, CEO & Representative Director	770.46k	N/A	1959
Mr. Motohiko Kawaguchi	CFO, Managing Executive Officer & Head of Global Finance	N/A	N/A	N/A
Mr. Yutaka Osawa M.B.A.	CCO, Executive VP & Representative Director	469.5k	N/A	1959
Kazuki Nemoto	Head of Global Legal	N/A	N/A	N/A
Satoko Yoshida M.B.A.	Head of Global Corporate Communications	N/A	N/A	N/A
Hiroshi Sonekawa	Managing Executive Officer, VP and Head of Sales & Marketing Division	N/A	N/A	N/A
Wataru Murata M.B.A.	Chief People Officer & Head of Global Human Resources	N/A	N/A	N/A
Mr. Takeyoshi Yamashita Ph.D.	Chief Medical Officer, Senior Managing Executive Officer & Director	N/A	N/A	1961
Yasuo Fujii M.B.A.	Chief Strategy Officer, VP & Managing Executive Officer	N/A	N/A	N/A
Jean-David Rafizadeh-Kabe J.D., M.D.	Head of Global Operational Transformation	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Corporate governance

Kyowa Hakko Kirin Co., Ltd.’s ISS governance QualityScore as of 1 April 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 4; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.